Once somebody has been diagnosed with Neuroendocrine prostate cancer there is really not much that can be done. Getting a scan to see where it is it is not really going to change the treatment plan.

There was one DLL3 study (UCSF Aggarwal) that was a possible trial for prostate cancer patients, but they changed it about a year ago so that only breast cancer patients are involved. I’m not heard that they changed it back but there are many studies in the works, see below.

The two people I know who have had neuroendocrine cancer have died within a year. It is one thing I worry about since I’ve been on these drugs for so many years and that has been found to be one of the factors to cause it. Have heard of Neuroendocrine patients living a couple of years maybe more.

From: MSKCC TargetDonc onclive ascopubs
There are several ongoing clinical studies targeting DLL3 in neuroendocrine prostate cancer (NEPC):
• Memorial Sloan Kettering Cancer Center (MSK) is opening a clinical trial testing a radioactive ligand that targets DLL3 in people with metastatic NEPC. Patients will first be screened for DLL3 expression and, if eligible, will receive the targeted therapy.
• The SKYBRIDGE trial (NCT05652686) is a phase 1/2 study evaluating peluntamig (PT217), which targets DLL3 and CD47, in patients with DLL3-expressing neuroendocrine carcinomas, including NEPC.
• A phase 1b study of tarlatamab, a DLL3-targeted bispecific T-cell engager, is ongoing in patients with metastatic NEPC, showing manageable safety and encouraging anti-tumor activity in DLL3-positive cases (NCT04702737).
• Other agents like HPN328, another DLL3-targeted T-cell engager, are also being tested in neuroendocrine prostate cancer.
These studies reflect a strong research focus on DLL3 as a therapeutic target for NEPC.